The Role of Regulatory Leadership in Healthcare

Impossibile aggiungere al carrello

Puoi avere soltanto 50 titoli nel carrello per il checkout.

Riprova più tardi

Rimozione dalla Lista desideri non riuscita.

Riprova più tardi

Non è stato possibile aggiungere il titolo alla Libreria

Per favore riprova

Non è stato possibile seguire il Podcast

Per favore riprova

Esecuzione del comando Non seguire più non riuscita

The Role of Regulatory Leadership in Healthcare

Ascolta gratuitamente

Vedi i dettagli del titolo

Approval alone does not guarantee patient access, and for pharmaceutical leaders, that gap is becoming one of the industry's most pressing challenges. Regulatory strategy can no longer function as a back-end compliance exercise. It now plays a central role in determining how quickly therapies reach patients, how organisations scale across markets, and whether innovation delivers measurable healthcare impact.In a recent episode of The Chain Reaction podcast, Trisha Pillay spoke with Dineshree Naiker, co-founder of Umsebe Healthcare, about why regulation should be viewed as strategic infrastructure rather than administrative oversight. Drawing on three decades of experience across public sector pharmacy, multinational corporations, and specialist consultancy, Naiker explained why ethical, well-executed regulatory frameworks are essential to sustainable access, innovation, and long-term healthcare equity.Naiker’s perspective is shaped by a career that began during South Africa’s democratic transition, when healthcare access became a national priority and regulation emerged as a key mechanism for improving patient outcomes. Today, she believes the industry must move beyond compliance-first thinking and rethink regulatory affairs as a driver of business resilience and public health impact.Regulatory Strategy Belongs at the BeginningThe instinct in many organisations is to treat regulatory approval as the finish line. Naiker's first and most insistent point is that this instinct is wrong and costly."Regulatory leadership unequivocally must begin long before submission," she says. "In complex markets such as the ones that we operate in, regulatory foresight must anticipate manufacturing realities, supply chain constraints, pharmacovigilance capacity, pricing structures, and reimbursement models."The consequence of delaying regulatory thinking until late in the development cycle is not merely a slower approval process. It is friction that compounds, unanticipated data requirements, commercial instability, and ultimately, delayed patient access. If regulatory strategy is embedded early enough, Naiker argues, it becomes an enabler, reducing downstream risk and ensuring that once approval is achieved, the system can actually support ongoing supply and long-term patient value.Supply Chain Resilience Is a Governance ProblemWhen the conversation turns to supply chain stability, Naiker is direct about how the challenge is typically mischaracterised."Supply chain resilience is often oversimplified as logistics. In reality, what we're talking about is governance, and it's governance that is quite layered with complexity."The structural pressures she identifies are multiple and rarely isolated, with aggressive price erosion that makes sustainability fragile when pricing becomes the dominant metric; procurement consolidation that reduces the number of viable suppliers and increases concentration risk; manufacturing consolidation at a global level that disadvantages lower-volume markets through ever-increasing minimum order quantities; and currency dynamics that mean markets with stronger currencies are prioritised during periods of global supply pressure.Value Must Be Built In at InceptionThe thread running through every dimension of Naiker's argument is regulatory, supply chain, market access, and the concept of value-based alignment. It is where the conversation becomes most directly actionable for pharma leaders."Value should be built into a product at inception, and definitely not bolted on post-approval," she says. "Rather than focusing purely on price reduction, we need to examine the factors that affect uptake of medicines and long-term value."This means procurement frameworks that consider total cost of care and patient outcomes alongside unit price. It means stakeholder alignment, across manufacturers, distributors, funders, medical schemes, and procurement bodies around what a product actually delivers to the healthcare system rather than what it costs at the point of transaction. It also means recognising that a product appearing more expensive upfront may deliver significant cost effectiveness through improved adherence, reduced complications, and enhanced system efficiency. For more information on this visit Umsebe Healthcare, or connect with Dineshree Naiker on LinkedIn.TakeawaysRegulatory leadership must begin long before submission.Regulatory strategy is essential for sustainable access.Supply chain resilience is often oversimplified as logistics.Value should be built into a product at inception.Approval alone does not create access; alignment is key.Managing supply stability is a continuous balancing act.Ethical sourcing and sustainable distribution are achievable with alignment.Challenges in healthcare access are interconnected globally.A fresh coordinated approach is needed across stakeholders.Chapters00:00 Introduction to Pharmaceutical Healthcare Strategies01:24 Dineshree Naiker's Journey in ...

Ancora nessuna recensione